1.The therapeutic effect of Tyrosine kinase inhibitor (TKIs) was significantly improved in patients with EGFR gene amplification (80% of lung cancer).
2.The utilization of screening of NSCLC patients for TKIs treatment
3. EGFR gene amplification can also occur in lung cancer, head and neck cancer, ovarian cancer, cervical cancer, bladder cancer, esophageal cancer and other more tumors.